Key statistics
As of last trade, Apellis Pharmaceuticals Inc (APLS:NSQ) traded at 37.52, 12.03% above the 52 week low of 33.49 set on Aug 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.24 |
---|---|
High | 37.84 |
Low | 36.10 |
Bid | 37.43 |
Offer | 37.52 |
Previous close | 35.63 |
Average volume | 1.37m |
---|---|
Shares outstanding | 121.77m |
Free float | 104.38m |
P/E (TTM) | -- |
Market cap | 4.34bn USD |
EPS (TTM) | -2.74 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 16:23 BST.
More ▼
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
- Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
More ▼